We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Cytokinetics Inc | NASDAQ:CYTK | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.35% | 65.28 | 64.53 | 66.50 | 66.52 | 64.53 | 65.74 | 847,907 | 21:00:10 |
From May 2019 to May 2024
By Michael Dabaie
Amgen Inc. (AMGN), Cytokinetics Inc. (CYTK) and Servier announced that new results from a Phase 2 trial showed omecamtiv mecarbil in patients with heart failure with reduced ejection fraction was associated with neutral or improved measures of diastolic function.
In addition to previously reported improvements in cardiac contractility measures, measures of diastolic function weren't different from placebo and, for some measures, trended towards improvement, the companies said.
In the COSMIC-HF trial, 448 patients were randomly assigned to omecamtiv mecarbil or placebo in a double-blind fashion for 20 weeks.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 18, 2019 09:31 ET (14:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Cytokinetics Chart |
1 Month Cytokinetics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
